- $95.22m
- $105.83m
- $24.38m
- 16
- 16
- 73
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -146.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42.68 | 47.39 | 49.19 | 24.75 | 24.38 | 33.3 | 53.7 | -10.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Directors
- Kevin Rakin CHM (61)
- Ronald Lloyd PRE (60)
- Matthew Ferguson CFO (53)
- Darryl Roberts EVP (59)
- Jerome Riebman EXO (67)
- Thomas Englese OTH (47)
- W. Matthew Zuga DRC (56)
- Maybelle Jordan IND (55)
- Brigid Makes IND (64)
- C. Randall Mills IND (49)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 6th, 2015
- Public Since
- October 8th, 2020
- No. of Shareholders
- 29
- No. of Employees
- 51
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 40,865,754
- Address
- 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING, 20904
- Web
- https://elutia.com/
- Phone
- +1 2402471143
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ELUT
Q1 2025 Elutia Inc Earnings Release
Elutia Inc Annual Shareholders Meeting
Elutia Inc Annual Shareholders Meeting
Q2 2025 Elutia Inc Earnings Release
Similar to ELUT
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Elutia share price?
As of Today at 20:25 UTC, shares in Elutia are trading at $2.33. This share price information is delayed by 15 minutes.
How has the Elutia share price performed this year?
Shares in Elutia last closed at $2.33 and the price had moved by -19.38% over the past 365 days. In terms of relative price strength the Elutia share price has underperformed the S&P500 Index by -25.58% over the past year.
What are the analyst and broker recommendations for Elutia?
The overall consensus recommendation for Elutia is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Elutia dividend yield?
Elutia does not currently pay a dividend.
Does Elutia pay a dividend?
Elutia does not currently pay a dividend.
When does Elutia next pay dividends?
Elutia does not currently pay a dividend.
How do I buy Elutia shares?
To buy shares in Elutia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Elutia?
As of the previous close price of $2.33, shares in Elutia had a market capitalisation of $95.22m.
Where are Elutia shares listed?
Here are the trading details for Elutia:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ELUT
What kind of share is Elutia?
Based on an overall assessment of its quality, value and momentum Elutia is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Elutia share price forecast for 2025?
The analyst consensus target price for shares in Elutia is $9.00. That is 286.27% above the last closing price of $2.33.
Analysts covering Elutia currently have a consensus Earnings Per Share (EPS) forecast of -$0.77 for the next financial year.
Find out moreWhat is the trend in the Elutia share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elutia. Over the past six months, its share price has underperformed the S&P500 Index by -25.81%.
As of the last closing price of $2.33, shares in Elutia were trading -32.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Elutia PE Ratio?
The Elutia PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Elutia?
Elutia's management team is headed by:
- Kevin Rakin - CHM
- Ronald Lloyd - PRE
- Matthew Ferguson - CFO
- Darryl Roberts - EVP
- Jerome Riebman - EXO
- Thomas Englese - OTH
- W. Matthew Zuga - DRC
- Maybelle Jordan - IND
- Brigid Makes - IND
- C. Randall Mills - IND